Display options
Cite
Sánchez-Romero C, Bologna-Molina R, González-González R, et al. Comparison of orosomucoid-1 immunoexpression and angiogenesis between oral squamous cell carcinoma cases with different histological grades. J Oral Maxillofac Pathol. 2021;25(2):368doi: 10.4103/0973-029X.325243.
Sánchez-Romero, C., Bologna-Molina, R., González-González, R., Salazar-Rodríguez, S., & Mendoza, N. B. (2021). Comparison of orosomucoid-1 immunoexpression and angiogenesis between oral squamous cell carcinoma cases with different histological grades. Journal of oral and maxillofacial pathology : JOMFP, 25(2), 368. https://doi.org/10.4103/0973-029X.325243
Sánchez-Romero, Celeste, et al. "Comparison of orosomucoid-1 immunoexpression and angiogenesis between oral squamous cell carcinoma cases with different histological grades." Journal of oral and maxillofacial pathology : JOMFP vol. 25,2 (2021): 368. doi: https://doi.org/10.4103/0973-029X.325243
Sánchez-Romero C, Bologna-Molina R, González-González R, Salazar-Rodríguez S, Mendoza NB. Comparison of orosomucoid-1 immunoexpression and angiogenesis between oral squamous cell carcinoma cases with different histological grades. J Oral Maxillofac Pathol. 2021 May-Aug;25(2):368. doi: 10.4103/0973-029X.325243. Epub 2021 Aug 31. PMID: 34703136; PMCID: PMC8491347.
Copy Download .nbib Format: NLM
Share it on

J Oral Maxillofac Pathol. 2021 May-Aug;25(2):368. doi: 10.4103/0973-029X.325243. Epub 2021 Aug 31.

Comparison of orosomucoid-1 immunoexpression and angiogenesis between oral squamous cell carcinoma cases with different histological grades.

Journal of oral and maxillofacial pathology : JOMFP

Celeste Sánchez-Romero, Ronell Bologna-Molina, Rogelio González-González, Sirced Salazar-Rodríguez, Nataly Barreiro Mendoza

Affiliations

  1. Molecular Pathology Area, School of Dentistry, University of the Republic, Montevideo, Uruguay.
  2. Department of Research, School of Dentistry, Juarez University of the State of Durango, Durango, México.
  3. Department of Anatomical Pathology, National Institute of Oncology and Radiobiology, Havana, Cuba.
  4. Department of Anatomical Pathology, Society to Fight Cancer, Núcleo Manabí.
  5. Department of Oral Pathology Research, School of Dentistry, University of San Gregorio Portoviejo, Portoviejo, Manabí, Ecuador.

PMID: 34703136 PMCID: PMC8491347 DOI: 10.4103/0973-029X.325243

Abstract

BACKGROUND: Oral squamous cell carcinoma (OSCC) is the most common malignancy in this region, and thus, further elucidation of its tumoral mechanisms is important. One of the main roles of the acute-phase protein orosomucoid-1 (ORM1) is the promotion of angiogenesis, which is key for tumor nutrition and growth.

AIM: Our aim was to evaluate the immunohistochemical expression of ORM1 and the angiogenic activity indicated by microvascular density (MVD) in OSCC samples according to histological grade.

MATERIALS AND METHODS: Formalin-fixed, paraffin-embedded sections from 45 OSCC cases were submitted to immunohistochemistry: 25 were well-differentiated OSCC, 18 were moderately differentiated OSCC and 2 were poorly differentiated OSCC. ORM1 staining was evaluated by a semiquantitative method, and CD34-positive blood vessels were quantified to calculate the MVD. The results were statically analyzed.

RESULTS: All cases exhibited immunoexpression of ORM1 and CD34. However, no significant differences were found between the expression of both markers among the histological grades. In addition, the presence of ORM1 in inflammatory cells and in the extracellular matrix was detected in most cases.

CONCLUSION: These results suggest that the induction of angiogenesis is not the main role of ORM1 in OSCC and may be associated with the regulation of the immune/inflammatory response or the transport of protumoral molecules, such as sialyl-Lewis X or phorbol esters, which requires confirmation in future studies.

Copyright: © 2021 Journal of Oral and Maxillofacial Pathology.

Keywords: Acute-phase proteins; angiogenesis; immunohistochemistry; oral cancer; orosomucoid-1 protein

Conflict of interest statement

There are no conflicts of interest.

References

  1. Cancers (Basel). 2018 Sep 22;10(10): - PubMed
  2. Vet Res Commun. 2011 Jan;35(1):1-11 - PubMed
  3. Eur Arch Otorhinolaryngol. 1995;252(3):159-62 - PubMed
  4. Biochim Biophys Acta. 2000 Oct 18;1482(1-2):157-71 - PubMed
  5. Nat Commun. 2018 Sep 5;9(1):3598 - PubMed
  6. J Clin Pathol. 2001 Dec;54(12):940-4 - PubMed
  7. Lancet. 1994 Oct 29;344(8931):1237-8 - PubMed
  8. J Dent Educ. 2001 Nov;65(11):1282-90 - PubMed
  9. Am J Physiol. 1999 Feb;276(2):H530-4 - PubMed
  10. Arch Dermatol. 2001 Sep;137(9):1169-73 - PubMed
  11. Oral Oncol. 2017 Sep;72:38-47 - PubMed
  12. Mol Cancer Ther. 2014 Mar;13(3):585-95 - PubMed
  13. Phytother Res. 2011 Jul;25(7):1018-23 - PubMed
  14. N Engl J Med. 1991 Jan 3;324(1):1-8 - PubMed
  15. Pathol Oncol Res. 2001;7(2):111-7 - PubMed
  16. APMIS. 2017 Feb;125(2):128-133 - PubMed
  17. J Oral Pathol Med. 2004 Nov;33(10):601-6 - PubMed
  18. Nat Commun. 2013;4:2873 - PubMed
  19. Cancer Res. 1988 Jan 1;48(1):1-8 - PubMed
  20. Med Sci Monit. 2007 Apr;13(4):CR195-200 - PubMed
  21. Oral Oncol. 1997 Sep;33(5):369-74 - PubMed
  22. Exp Cell Res. 2009 Nov 1;315(18):3201-9 - PubMed
  23. Mol Carcinog. 2006 Jun;45(6):381-8 - PubMed
  24. Rom J Morphol Embryol. 2015;56(2):465-73 - PubMed
  25. Eur J Med Res. 2009 Jul 22;14(7):315-9 - PubMed
  26. PLoS One. 2012;7(8):e41387 - PubMed
  27. An Med Interna. 2001 Feb;18(2):100-4 - PubMed
  28. Proteomics. 2005 Nov;5(16):4296-304 - PubMed
  29. Histol Histopathol. 2005 Jan;20(1):91-7 - PubMed

Publication Types